Document:

Exhibit 10.6

    

    

    

    
      Summary of BSA Plans

      

      

      Warrants, or BSAs, are typically granted by our executive board to third-party service providers and members of our supervisory board that are not eligible
        for either founders’ warrants or stock options.  Warrants entitle a holder to exercise the warrants for the underlying vested shares at an exercise price per share determined by our executive board that is meant to reflect the fair market value of
        an ordinary share on the date of grant.  In addition to such exercise price, warrants are subscribed for at a price determined by the executive board that is meant to reflect the fair market value of the applicable warrants on the grant date.

      

      

      Administration.
          Our shareholders, or pursuant to delegations granted by our shareholders, our executive board (with the prior approval of the supervisory board), determine the recipients of the warrants, the grant dates, the number and exercise price of the
          warrants to be granted, the number of shares issuable upon exercise of the warrants and certain other terms and conditions of the warrants, including the period of their exercisability and their vesting schedule.  There is no legal limitation to
          the size of the warrant pool.

      

      

      Warrants Terms. 
          The term of warrants granted before June 25, 2015, as well as the BSA2015-2(a), the BSA2018-2, the BSA2019-1 and the BSA2020 is ten years from the date of grant.  The term of warrants granted after June 25, 2015 to March 6, 2018 as well as the BSA2015-2(b) is five years from the date of grant.

      

      

      Additionally, unless otherwise decided by our supervisory and executive boards, the BSA2016-1 and the BSA2017 must be exercised within
        six months from (i) the death or disability of the holder or (ii) the termination of the holder from employment with us or any of our affiliates during such ten-year period.

      

      

      Change in Control. 
          The terms of the BSA2015-1, the BSA2016-1 and the warrants granted from January 7, 2017 onwards provide that, unless otherwise decided by our supervisory and executive boards, in the event of a merger into another
          corporation or of the sale by one or several shareholders, acting alone or in concert, of our Company to one or several third parties of a number of shares resulting in a change of control (a “Liquidity Event”), the right of any holder to
          exercise outstanding warrants will be accelerated so that all such warrants may be exercised with effect immediately prior to the completion of the relevant Liquidity Event, subject, if applicable, to continued service by the warrant holder. Any
          warrant not exercised for any reason prior to the date of completion of the relevant Liquidity Event will automatically lapse.

      

      

      The terms of the BSA2015-2(a) and the BSA2015-2(b) provide their holder with the right to exercise all of his or her warrants in the
        event of a change of control (i.e., through a merger, a transfer of shares or assets, an operation on share or liquidation).

      

      

      
        
          

      

      Specified Exercise Thresholds. The BSA04-2012 and the BSA2013 become exercisable pursuant to their vesting schedule, provided
          that on the day these warrants are exercised, the relevant holder, when a supervisory board member, has attended at least 75% of the supervisory board meetings held during the period preceding the exercise of these warrants or, as the case may
          be, the date the holder ceases to be part of the group.

      

      

      The BSA2014, the BSA2015-1, the BSA2016-01-Ordinary the BSA2017, the BSA2018, the BSA2019-01
        and the BSA2020 become exercisable pursuant to their vesting schedule, provided that (i) on the day these warrants are exercised, the relevant holder, when a supervisory board member, has attended at least 75% of the supervisory board
        meetings held during the period preceding the exercise of these warrants or, as the case may be, the date the holder ceases to be part of the group and (ii) the market value of a Company share is at least equal to €40.

      

      

      The BSA2015-2(a) and BSA2015-2(b) become exercisable pursuant to their vesting schedule, provided that on the day these warrants are
        exercised, the market value of a Company share is at least equal to €50.

      

      

      The BSA2016-01-Performance may be exercised, subject to achievement of the following targets:  (1) up to 15% of these warrants may be exercised
        if the number of patients under treatment is at least equal to 200, (2) an additional 15% of these warrants may be exercised if the number of patients under treatment is at least equal to 300, (3) an additional 30% of these warrants may be
        exercised if the number of patients under treatment is at least equal to 400 and (4) an additional 40% of these warrants may be exercised if the number of patients under treatment is at least equal to 500.

      

      

      The BSA2016-02 the BSA2018-01 and the BSA2018-02 become exercisable pursuant to their vesting schedule,
        provided that on the day these warrants are exercised, the market value of a Company share is at least equal to €40.

      

      

      Exercise Price. 
          Provided that the relevant, specified thresholds as described above are satisfied, each BSA04-2012 gives the right to subscribe to one share of Nanobiotix at the fixed price of €6 (issue premium included); each BSA2013 gives
          the right to subscribe to one share of Nanobiotix at the fixed price of €6.37 (issue premium included); each BSA2014 and BSA2015-1 gives the right to subscribe to one share of Nanobiotix at the fixed price of €17.67 (issue
          premium included); each BSA2015-2(a) and BSA2015-2(b) gives the right to subscribe to one share of Nanobiotix at the fixed price of €19.54 (issue premium included); each BSA2016-01-Ordinary and BSA2016-01-Performance
          gives the right to subscribe to one share of Nanobiotix at the fixed price of €13.74 (issue premium included); each BSA2016-2 gives the right to subscribe to one share of Nanobiotix at the fixed price of €15.01 (issue premium
          included); each BSA2017 gives the right to subscribe to one share of Nanobiotix at the fixed price of €15.76 (issue premium included); each BSA2018 and BSA2018-01 gives the right to subscribe to one share of
          Nanobiotix at the fixed price of €13.55 (issue premium included), each BSA2018-02 gives the right to subscribe to one share of Nanobiotix at the fixed price of €16.102 (issue premium included); each BSA2019-01 gives the
          right to subscribe to one share of Nanobiotix at the fixed price of €11.66 (issue premium included), and; each BSA2020 gives the right to subscribe to one share of Nanobiotix at the fixed price of €6.59 (issue premium included).

      

      

      
        
          

      

      Vesting Period.
          Subject to the specified thresholds described above, all of the outstanding BSA are vested..

      

      

      Final Date for Exercising Warrants.  The BSA04-2012 warrants will expire May 4, 2022; the BSA2013 warrants will expire April 10,
          2023; the BSA2014 warrants will expire September 16, 2024; the BSA2015-1 warrants will expire February 10, 2025; the BSA2015-2(a) warrants will expire June 25, 2025; the
          BSA2015-2(b) warrants will expire June 25, 2020; the BSA2016-01 warrants will expire February 2, 2021; the BSA2016-02 warrants will expire November 3, 2021; the BSA2017 warrants
          will expire January 7, 2022; the BSA2018 warrants will expire March 6, 2023; the BSA2018-02 warrants will expire July 27, 2028, the BSA2019-1 will expire March 29, 2029, and; the BSA2020
          will expire March 17, 2030.Exhibit 10.7

    

    

    

    
      Summary of BSPCE Plans

      

      

      Founders’ warrants or BSPCE may only be issued by growth companies meeting certain criteria, which we no longer meet. Therefore, notwithstanding any shareholder authorization, under applicable law we can no longer
        issue founders’ warrants.

      

      

      Founders’ warrants, or BSPCEs, were granted only to our employees who are French tax residents, as they provide favorable tax and social security treatment for French tax residents.  Founders’ warrants could also be
        granted to our corporate officers having an employee tax status at the time the founders’ warrants are granted.

      

      

      Founders’ warrants entitle a holder to exercise the warrant for the underlying vested shares at an exercise price per share determined by our executive board and at least equal to the fair market value of an ordinary
        share on the date of grant.

      

      

      Founders’ warrants are not transferable and may not be sold, pledged, assigned, hypothecated, transferred or disposed of in any manner other than by will or by laws of descent or distribution and may be exercised,
        during the lifetime of the founders’ warrant holder, only by its holder.

      

      

      Administration.  Our shareholders, or pursuant to
          delegations granted by our shareholders, our executive board determined (with prior approval of the supervisory board) the recipients of the founders’ warrants, the grant dates, the number and exercise price of the founders’ warrants to be
          granted, the number of shares issuable upon exercise of the founders’ warrants and certain other terms and conditions of the founders’ warrants, including the period of their exercisability and their vesting schedule. As stated above, we can no
          longer issue founders’ warrants.

      

      

      Founders’ Warrants.  The term of each founders’ warrant is ten years from the date of grant
          or, unless otherwise decided by our supervisory and executive boards, six months from (i) the death or disability of the holder or (ii) the termination of the holder’s employment with us or any of our affiliates during such ten-year period.

       

        

      By exception:

       

      

      	◾	
              the term of the founders’ warrants granted on May 4, 2012 was seven years from the date of grant;

            

      	◾	
              neither the founders’ warrants granted on May 4, 2012, nor those granted on April 28, 2013, are subject to continuous employment; and

            

      	◾	
              on July 23, 2019, the executive board decided to lift, for two of our employees and for Mr. Bernd Muehlenweg, a former member of the executive board, the continued service condition and, where applicable, the performance conditions to
                which the exercise of certain founders’ warrants was subject, notwithstanding the termination of their employment agreement or corporate office.

            

      

      

      Change in Control.  The terms of the founders’ warrants generally provide that, unless
          otherwise decided by our supervisory and executive boards, in the event of a merger into another corporation or of the sale by one or several shareholders, acting alone or in concert, of our Company to one or several third parties of a number of
          shares resulting in a change of control (a ‘‘Liquidity Event’’), the right of holders to exercise outstanding founders’ warrants will be accelerated so that all of such shares may be exercised with effect immediately prior to the completion of
          the relevant Liquidity Event.  Any founders’ warrant not exercised for any reason on or prior to the date of completion of the relevant Liquidity Event will automatically lapse.

      

      

      
        

        
          

        

      

      By exception:

       

      

      	◾	
              for founders’ warrants granted on May 4, 2012, Liquidity Events are limited to the filing of a tender offer for our shares – in such event, the number of shares that may be exercised by holders is subject to the price per share offered
                in the tender offer; and

            

      	◾	
              the founders’ warrants granted on April 10, 2013 do not to include any right of acceleration in the event of a change in control.

            

      

      

      Specified Exercise Thresholds.  The BSPCE2016-Performance may be exercised as of the date of their grant, subject to the achievement of the following targets: (1) up to 15% of these warrants may be exercised if the number of patients under treatment is
          at least equal to 200, (2) an additional 15% of these warrants may be exercised if the number of patients under treatment is at least equal to 300, (3) an additional 30% of these warrants may be exercised if the number of patients under treatment
          is at least equal to 400 and (4) an additional 40% of these warrants may be exercised if the number of patients under treatment is at least equal to 500.

      

      

      Exercise Price.  Provided that the relevant specified thresholds as described above are
          satisfied, each BSPCE2012-2 gives the holder the right to purchase up to one (1) ordinary share for €6.63; each BSPCE08-2013 gives the holder the right to purchase up to one (1) ordinary share for €5.92; each BSPCE09-2014 gives the holder the right to
          purchase up to one (1) ordinary share for €18.68; each BSPCE2015-01 gives the holder the right to purchase up to one (1) ordinary share for €18.57; each BSPCE2015-03 gives the holder the right to purchase up to one (1) ordinary share for €20.28; each BSPCE2016
          and BSPCE2016-Performance gives the holder the right to purchase up to one (1) ordinary share for €14.46, and; each BSPCE2017-Ordinary and BSPCE2017 gives the holder the right to purchase up to one (1) ordinary share for €15.93.

      

      

      Vesting Period.

      

      

      All of the BSPCE2012-2, the BSPCE08-2013, the BSPCE09-2014, BSPCE2015-01, the BSPCE2015-03,
        the BSPCE2016-Ordinary, the BSPCE2017 and the BSPCE2017-Ordinary can be exercised.

      

      

      As of May 1, 2020, 30% of the BSPCE2016-Performance can be exercised, it being specified that, on July 23, 2019, the executive board
        decided to lift, for Mr. Bernd Muehlenweg (a member of our executive board until June 20, 2019), the performance conditions to which the exercise of his 11,500 BSPCE2016
          Performance was subject, notwithstanding the termination of his employment agreement and his corporate office within the Company. Accordingly, all of Mr. Bernd Muehlenweg’s BSPCE2016 Performance may be exercised.

      

      

      Final Date for Exercising Warrants.  The BSPCE2012-2 will expire on December 18, 2022; the BSPCE08-2013

          will expire on August 28, 2023; the BSPCE09-2014 will expire on September 16,
          2024; the BSPCE2015-01 will expire on February 10, 2025; the BSPCE2015-03 will expire on June 10, 2025; the BSPCE2016 and the BSPCE2016 Performance will expire on February
          2, 2026; and the BSPCE2017 and the BSPCE2017-Ordinary will expire on January 7, 2017.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00317-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00317-of-00352.parquet"}]]